Empagliflozin/Linagliptin and Dolutegravir Interaction

Understanding the Empagliflozin/Linagliptin and Dolutegravir Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Empagliflozin/Linagliptin belongs to the SGLT2 / DPP-4 Combination class and Dolutegravir belongs to the Integrase Strand Transfer Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Dolutegravir blocks the kidneys from filtering metformin out of your blood, which makes metformin levels rise. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Empagliflozin/Linagliptin has 11 total documented interactions on file in this dataset, and Dolutegravir has 28. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to lower your metformin dose or check your blood levels more often. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Empagliflozin/Linagliptin or Dolutegravir based on a web page, speak with your prescriber or pharmacist before making any change.